Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProApix Study of apixaban effects on thrombin generation in multiple myeloma and total knee replacement
2024-515329-27-00Phase 4Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban in venous thromboembolism (VTE) (2 cohorts), sponsored by CHU Saint-Etienne. Primary endpoint: Endogenous thrombin potential at peak apixaban concentration. Planned start Jun 2025; status: authorised.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on 2024-515329-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515329-27-00.